Pfizer and Astellas' Padcev Antibody-Drug Conjugate under Review for Bladder Cancer Treatment in China

Thursday, 28 March 2024, 15:54

Pfizer and Astellas' Padcev, an antibody-drug conjugate, has been accepted for review in China for its potential use as a first-line treatment for bladder cancer. This move signifies a significant step in bringing innovative therapies to patients in need. The acceptance for review in China opens up new market opportunities for Pfizer and Astellas.
https://store.livarava.com/de152931-ed1b-11ee-8904-87cc5c87fb08.jpg
Pfizer and Astellas' Padcev Antibody-Drug Conjugate under Review for Bladder Cancer Treatment in China

Pfizer and Astellas' Joint Venture

Astellas and Pfizer's antibody-drug conjugate, Padcev, has been accepted for review in China for first-line treatment of bladder cancer.

Key Highlights:

  • Padcev under review in China for expanding treatment options

This development indicates the companies' commitment to advancing cancer therapies globally.


This article was prepared using information from open sources in accordance with the principles of Ethical Policy. The editorial team is not responsible for absolute accuracy, as it relies on data from the sources referenced.


Related posts


Newsletter

Get the most reliable and up-to-date financial news with our curated selections. Subscribe to our newsletter for convenient access and enhance your analytical work effortlessly.

Subscribe